Clinical Trial Update: Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update involving anrotinib combined with capecitabine for metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anrotinib (anrotinib)
• Capecitabine (capecitabine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Metastatic Triple-Negative Breast Cancer | Phase 2 | Status: UNKNOWN